AATec Medical GmbH
AATec Medical GmbH is a biotechnology company dedicated to developing new therapeutics for respiratory diseases with high medical need and global societal impact. They focus on a multi-product platform based on recombinant alpha-1 antitrypsin (AAT) to treat inflammatory diseases, viral infections, and rare diseases. Their mission is to address the growing demand for new treatment options in respiratory medicine by leveraging innovative inhalation technology and recombinant manufacturing processes. The company was founded by a team of experts with extensive experience in clinical research, biopharmaceutical development, and product industrialization, aiming to provide accessible and effective solutions worldwide.
Industries
Nr. of Employees
small (1-50)
AATec Medical GmbH
Am Klopferspitz 19, 82152 Planegg-Martinsried, Germany
Products
Inhaled recombinant alpha-1 antitrypsin therapeutic platform (lead candidate)
A development-stage drug platform based on a recombinant variant of alpha-1 antitrypsin formulated for inhalation to treat inflammatory and infectious respiratory diseases; designed for targeted airway delivery to achieve local therapeutic levels.
Inhaled recombinant alpha-1 antitrypsin therapeutic platform (lead candidate)
A development-stage drug platform based on a recombinant variant of alpha-1 antitrypsin formulated for inhalation to treat inflammatory and infectious respiratory diseases; designed for targeted airway delivery to achieve local therapeutic levels.
Services
Technical collaboration to design and industrialize nebulizer/inhaler devices for delivery of inhaled biologics, delivered via joint development with device manufacturing partners.
Application of lung-on-a-chip systems and computational simulations to assess lung distribution and preclinical effects of inhaled therapeutics prior to clinical studies.
Technical collaboration to design and industrialize nebulizer/inhaler devices for delivery of inhaled biologics, delivered via joint development with device manufacturing partners.
Application of lung-on-a-chip systems and computational simulations to assess lung distribution and preclinical effects of inhaled therapeutics prior to clinical studies.
Expertise Areas
- Respiratory drug development
- Biologics manufacturing and CMC
- Inhalation and aerosol drug delivery
- Preclinical and translational R&D
Key Technologies
- Recombinant protein production (bioprocessing)
- Protein inhalation formulation
- Aerosolization and nebulization technology
- Inhaler device engineering
News & Updates
Funding from SPRIND and Family Offices accelerates preparation of ATL-105 for clinical development in lead indication non-CF related bronchiectasis by 2026.
Leading Expert in Respiratory Medicine Supporting AATec in Product Development in Non-CF Bronchiectasis.
Major advancements in the development of ATL-105 for the treatment of inflammatory lung diseases, including clinical trial in non-cystic fibrosis bronchiectasis to start in 2025.
Funding from SPRIND and Family Offices accelerates preparation of ATL-105 for clinical development in lead indication non-CF related bronchiectasis by 2026.
Leading Expert in Respiratory Medicine Supporting AATec in Product Development in Non-CF Bronchiectasis.
Major advancements in the development of ATL-105 for the treatment of inflammatory lung diseases, including clinical trial in non-cystic fibrosis bronchiectasis to start in 2025.